QR Pharma Awarded Funding by The Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease
3/6/2012 8:43:16 AM
BERWYN, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR) a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the company $468,000 to conduct research for the development of Posiphen® to treat PD. QR will collaborate with Robert Nussbaum, MD, Professor, Department of Medicine and Chief, Division of Medical Genetics at the University of California, San Francisco and Jack T. Rogers, PhD, Associate Professor Psychiatry (Neuroscience) at the Massachusetts General Hospital, Genetics and Aging Research Unit.